A reliable plasma marker of platelet activation: Does it exist?

American Journal of Hematology

Volumn 70, Issue 2, 2002, Pages 139-144

  Gurney, David ^a   Lip, Gregory Y H ^a   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Beta thromboglobulin; Flow cytometry; Platelet factor 4; Platelets; Soluble P selectin

Indexed keywords

BETA THROMBOGLOBULIN; GLYCOCALICIN; PADGEM PROTEIN; THROMBOCYTE FACTOR 4;

ARTICLE; BLOOD SAMPLING; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKOCYTE AGGREGATION; PARTICLE SIZE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

BETA-THROMBOGLOBULIN; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; P-SELECTIN; PLATELET ACTIVATION; PLATELET FACTOR 4;

EID: 0036105627     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10097     Document Type: Article

References (86)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Platelet activation: Assessment and quantification
3. In vivo platelet activation in diabetes mellitus
4. Platelet contribution to the formation of metastatic foci: The role of cancer cell induced platelet activation
5. The role of platelets in ischaemic stroke
6. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection
7. Molecular markers of haemostasis activation in nephrotic syndrome
8. Review Article: Platelets in inflammatory bowel disease: Pathogenic role and therapeutic implications
9. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin. Pulmonary Embolism Prevention (PEP) trial
10. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspective acute myocardial infarction: ISIS-2
11. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men
12. Platelets, aspirin, and cardiovascular
13. Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis
14. Rapid change of platelet aggregability in acute hyperglycaemia. Detection by a novel laser-light scattering method
15. The clinical utility of flow cytometry in the study of platelets
16. Platelet function testing by flow cytometry
17. Elevated platelet-derived microparticle levels during unstable angina
18. Reticulated platelet values in normal and thrombocytopenic neonates
19. Diagnostic value of tests for reticulated platelets, plasma glycocalicin and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia
20. Circulating monocytes-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction
21. Reduction of monocytes-platelet interaction and monocytes activation in patients receiving antiplatelet therapy after coronary stent implantation
22. Immunocytochemical localisation of fibrinogen, platelet factor 4, and β-thromboglobulin in ultra thin cryostat sections of human blood platelets
23. Redistribution of alpha granules and their contents in thrombin stimulated platelets
24. Platelet alpha granules
25. Platelet factor 4 and adenosine diphosphate release during human platelet aggregation
26. Isolation and some properties of the heparin neutralising factor (PF4) released from human blood platelets
27. The release, distribution and clearance of human β-thromboglobulin and platelet factor 4
28. Influence of acetylsalicylic acid (1.0 g/day) on platelet survival time, beta thromboglobulin and platelet factor 4 in patients with peripheral arterial occlusive disease
29. The isolation of a platelet specific β-thromboglobulin and the detection of antiurokinase and antiplasmin released from thrombin aggregated washed human platelets
30. β-Thromboglobulin and platelet factor 4 in patients with cancer: Correlation with the stage of the disease and the effect of chemotherapy
31. Platelet factor 4 levels in patients with coronary artery disease
32. Detection of enhanced in-vivo platelet alpha granule release in different patient groups. Comparison of beta thromboglobulin, platelet factor 4 and thrombospondin assays
33. Reduction of β-thromboglobulin levels in diabetics controlled by an artificial pancreas
34. Platelet released proteins as molecular markers for the activation process
35. Circadian rhythm of plasma β-thromboglobulin in healthy human subjects
36. The variability of plasma beta thromboglobulin in healthy individuals
37. Plasma P-selectin is increased in thrombotic consumptive disorders
38. Studies on the liberation of β-thromboglobulin from human platelets in vitro
39. Influence of propranolol on platelet aggregation and thromboxane B2 production from platelet rich plasma and whole blood
40. Plasma levels of beta thromboglobulin and platelet factor four as indices of platelet activation in vivo
41. Standardisation of β-thromboglobulin and platelet factor 4 (PF4): A collaborative study to establish international standards for BTG and PF4
42. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in Atrial Fibrillation Trial III study
43. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: Effects of introducing ultra-low dose warfarin and aspirin
44. Platelet factor 4 and beta thromboglobulin in inflammatory bowel disease and giant cell arteritis
45. Platelets dense granules: Structure, function and implications for haemostasis
46. Platelets release their lysosomal content in vivo in humans upon activation
47. A platelet membrane protein expressed during platelet activation and secretion
48. Histidine phosphorylation of P-selectin upon stimulation of human platelets: A novel pathway for activation-dependant signal transduction
49. Comparison of β-thromboglobulin, flow cytometry and platelet aggregometry to study platelet activation
50. Circulating platelets show increased activation in patients with acute cerebral ischaemia
51. Characterisation of GMP-140 (P-selectin) as a circulating plasma protein
52. Soluble P-selectin assay: Importance of correct anticoagulant choice
53. A circadian rhythm may exist in healthy controls for soluble P-selectin and platelet count
54. Re-expression of functional P-selectin molecules on the endothelial cell surface by repeat stimulation with thrombin
55. The origin of P-selectin as a circulating plasma protein
56. Hypothesis: Is soluble P-selectin a new marker of platelet activation?
57. Soluble P-selectin is released from activated platelets in vivo during haemodialysis
58. Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopaenic purpura and haemolytic uraemic syndrome
59. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis
60. Elevated circulating P-selectin in insulin dependent diabetes mellitus
61. Effects of desmopressin on circulating P-selectin
62. Soluble P-selectin in patients with haematological and solid cancers
63. Increased soluble P-selectin in ischaemic heart disease: A new marker for the progression of atherosclerosis
64. Soluble P-selectin and the risk of future cardiovascular events
65. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation
66. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin
67. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function
68. Purification of glycoproteins IIb and IIIa from human platelet plasma membranes and characterisation of a calcium-dependent glycoprotein IIb-IIIa complex
69. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation
70. Gender differences in platelet GPIIb/IIIa activation
71. Adhesive signalling in platelets
72. Current status of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
73. Cloning and characterisation of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation
74. Human platelet glycoprotein V: Characterisation of the polypeptide and the related Ib-V-IX receptor system of adhesive, leucine-rich glycoproteins
75. Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA - Its use to follow platelet storage in transfusion
76. GPV is a marker of in vivo platelet activation - Study in a rat thrombosis model
77. Increased platelet glycoprotein V levels as an index of platelet activation in patients with coronary and peripheral atherosclerosis
78. Comparison of glycocalicin, thrombopoietin and reticulated platelet measurement as markers of platelet turnover in HIV samples
79. Indirect study of thrombopoiesis (TPO, reticulated platelets, glycocalicin) in patients with hereditary macro-thrombocytopenia
80. High levels of reticulated platelets and thrombopoietin characterize fetal platelets
81. Increase in glycocalicin levels in platelet concentrates stored in plasma or synthetic medium for 8 days: Comparison with other platelet activation markers
82. 2 blood levels and incipient system clotting in heparin free dialysis
83. 2 formation by atherosclerotic carotid artery: Comparison with normal aorta, saphenous vein and platelets
84. Platelet prostenoid receptors
85. Anti-platelet therapy
86. Aspirin and platelets: The anti-platelet action of aspirin and its role in thrombosis treatment and prophylaxis